Cargando…
Unraveling the Immunopathogenesis and Genetic Variants in Vasculitis Toward Development of Personalized Medicine
Leukocytoclastic vasculitis (LCV) is a systemic autoimmune disease characterized by the inflammation of the vascular endothelium. Cutaneous small vessel vasculitis (CSVV) and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) are two examples of LCV. Advancements in genomic te...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491767/ https://www.ncbi.nlm.nih.gov/pubmed/34621800 http://dx.doi.org/10.3389/fcvm.2021.732369 |
_version_ | 1784578793749348352 |
---|---|
author | Yap, Bryan Ju Min Lai-Foenander, Ashley Sean Goh, Bey Hing Ong, Yong Sze Duangjai, Acharaporn Saokaew, Surasak Chua, Caroline Lin Lin Phisalprapa, Pochamana Yap, Wei Hsum |
author_facet | Yap, Bryan Ju Min Lai-Foenander, Ashley Sean Goh, Bey Hing Ong, Yong Sze Duangjai, Acharaporn Saokaew, Surasak Chua, Caroline Lin Lin Phisalprapa, Pochamana Yap, Wei Hsum |
author_sort | Yap, Bryan Ju Min |
collection | PubMed |
description | Leukocytoclastic vasculitis (LCV) is a systemic autoimmune disease characterized by the inflammation of the vascular endothelium. Cutaneous small vessel vasculitis (CSVV) and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) are two examples of LCV. Advancements in genomic technologies have identified risk haplotypes, genetic variants, susceptibility loci and pathways that are associated with vasculitis immunopathogenesis. The discovery of these genetic factors and their corresponding cellular signaling aberrations have enabled the development and use of novel therapeutic strategies for vasculitis. Personalized medicine aims to provide targeted therapies to individuals who show poor response to conventional interventions. For example, monoclonal antibody therapies have shown remarkable efficacy in achieving disease remission. Here, we discuss pathways involved in disease pathogenesis and the underlying genetic associations in different populations worldwide. Understanding the immunopathogenic pathways in vasculitis and identifying associated genetic variations will facilitate the development of novel and targeted personalized therapies for patients. |
format | Online Article Text |
id | pubmed-8491767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84917672021-10-06 Unraveling the Immunopathogenesis and Genetic Variants in Vasculitis Toward Development of Personalized Medicine Yap, Bryan Ju Min Lai-Foenander, Ashley Sean Goh, Bey Hing Ong, Yong Sze Duangjai, Acharaporn Saokaew, Surasak Chua, Caroline Lin Lin Phisalprapa, Pochamana Yap, Wei Hsum Front Cardiovasc Med Cardiovascular Medicine Leukocytoclastic vasculitis (LCV) is a systemic autoimmune disease characterized by the inflammation of the vascular endothelium. Cutaneous small vessel vasculitis (CSVV) and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) are two examples of LCV. Advancements in genomic technologies have identified risk haplotypes, genetic variants, susceptibility loci and pathways that are associated with vasculitis immunopathogenesis. The discovery of these genetic factors and their corresponding cellular signaling aberrations have enabled the development and use of novel therapeutic strategies for vasculitis. Personalized medicine aims to provide targeted therapies to individuals who show poor response to conventional interventions. For example, monoclonal antibody therapies have shown remarkable efficacy in achieving disease remission. Here, we discuss pathways involved in disease pathogenesis and the underlying genetic associations in different populations worldwide. Understanding the immunopathogenic pathways in vasculitis and identifying associated genetic variations will facilitate the development of novel and targeted personalized therapies for patients. Frontiers Media S.A. 2021-09-21 /pmc/articles/PMC8491767/ /pubmed/34621800 http://dx.doi.org/10.3389/fcvm.2021.732369 Text en Copyright © 2021 Yap, Lai-Foenander, Goh, Ong, Duangjai, Saokaew, Chua, Phisalprapa and Yap. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Yap, Bryan Ju Min Lai-Foenander, Ashley Sean Goh, Bey Hing Ong, Yong Sze Duangjai, Acharaporn Saokaew, Surasak Chua, Caroline Lin Lin Phisalprapa, Pochamana Yap, Wei Hsum Unraveling the Immunopathogenesis and Genetic Variants in Vasculitis Toward Development of Personalized Medicine |
title | Unraveling the Immunopathogenesis and Genetic Variants in Vasculitis Toward Development of Personalized Medicine |
title_full | Unraveling the Immunopathogenesis and Genetic Variants in Vasculitis Toward Development of Personalized Medicine |
title_fullStr | Unraveling the Immunopathogenesis and Genetic Variants in Vasculitis Toward Development of Personalized Medicine |
title_full_unstemmed | Unraveling the Immunopathogenesis and Genetic Variants in Vasculitis Toward Development of Personalized Medicine |
title_short | Unraveling the Immunopathogenesis and Genetic Variants in Vasculitis Toward Development of Personalized Medicine |
title_sort | unraveling the immunopathogenesis and genetic variants in vasculitis toward development of personalized medicine |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491767/ https://www.ncbi.nlm.nih.gov/pubmed/34621800 http://dx.doi.org/10.3389/fcvm.2021.732369 |
work_keys_str_mv | AT yapbryanjumin unravelingtheimmunopathogenesisandgeneticvariantsinvasculitistowarddevelopmentofpersonalizedmedicine AT laifoenanderashleysean unravelingtheimmunopathogenesisandgeneticvariantsinvasculitistowarddevelopmentofpersonalizedmedicine AT gohbeyhing unravelingtheimmunopathogenesisandgeneticvariantsinvasculitistowarddevelopmentofpersonalizedmedicine AT ongyongsze unravelingtheimmunopathogenesisandgeneticvariantsinvasculitistowarddevelopmentofpersonalizedmedicine AT duangjaiacharaporn unravelingtheimmunopathogenesisandgeneticvariantsinvasculitistowarddevelopmentofpersonalizedmedicine AT saokaewsurasak unravelingtheimmunopathogenesisandgeneticvariantsinvasculitistowarddevelopmentofpersonalizedmedicine AT chuacarolinelinlin unravelingtheimmunopathogenesisandgeneticvariantsinvasculitistowarddevelopmentofpersonalizedmedicine AT phisalprapapochamana unravelingtheimmunopathogenesisandgeneticvariantsinvasculitistowarddevelopmentofpersonalizedmedicine AT yapweihsum unravelingtheimmunopathogenesisandgeneticvariantsinvasculitistowarddevelopmentofpersonalizedmedicine |